Shares of Cannabis Science Inc. (OTC: CBIS), a medical marijuana company, fell sharply in Monday’s trading session.

The penny stock of CBIS ended the day 10.03% lower at $0.0520, with volume up from daily average of 5.03 million to 7.51 million. The stock has fallen 25.29% in the last three trading sessions.

Cannabis Science recently announced that it is set to release its newest brand of OTC skin and nutraceutical product lines through its newest venture Phytiva Pharmaceuticals Inc.

Last week, CBIS also announced that it created Cannabis Science Research Foundation and looks forward to inaugural event in the near future.

• This newsletter has been helping traders make a killing on CBIS. Click here for a 25% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for CBIS
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

About InvestorSoup

InvestorSoup.com is committed to provide intelligent commentary and solid analysis of small cap stocks, micro-cap stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or “penny stock” market, which has traditionally been shunned by Wall Street. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.

Disclaimer

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication.

The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. BeaconEquity.com is a wholly owned subsidiary of BlueWave Advisors, LLC.